Get the Stockscreener App
1.76
5.88%
-0.11
Pre-market:
1.79
0.03
+1.70%
Invivyd Inc stock is traded at $1.76, with a volume of 2.95M.
It is down -5.88% in the last 24 hours and up +60.00% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$1.87
Open:
$1.86
24h Volume:
2.95M
Relative Volume:
0.42
Market Cap:
$211.45M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.898
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
-21.08%
1M Performance:
+60.00%
6M Performance:
+179.28%
1Y Performance:
+97.20%
1-Day Range:
$1.75
$2.00
1-Week Range:
$1.74
$2.34
52-Week Range:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.76 | 400.95M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
Invivyd Inc. stock momentum explainedJuly 2025 Macro Moves & Capital Protection Trading Alerts - newser.com
Will Invivyd Inc. stock gain from strong economyGlobal Markets & Detailed Earnings Play Alerts - newser.com
How institutional buying supports Invivyd Inc. stockWeekly Stock Analysis & Low Risk Growth Stock Ideas - newser.com
Backtesting results for Invivyd Inc. trading strategies2025 Key Lessons & Safe Entry Trade Signal Reports - newser.com
Invivyd Inc. stock volume spike explained2025 Market WrapUp & Verified Momentum Stock Watchlist - newser.com
Visual trend scoring systems applied to Invivyd Inc.July 2025 Update & Consistent Profit Alerts - newser.com
Why analysts upgrade Invivyd Inc. stockJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Using economic indicators to assess Invivyd Inc. potentialJuly 2025 Sector Moves & AI Enhanced Trading Alerts - newser.com
What drives Invivyd Inc stock priceHead and Shoulders Patterns & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Invivyd (NASDAQ:IVVD) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 156.9% in October - MarketBeat
Invivyd price target raised to $10 from $5 at H.C. Wainwright - MSN
HC Wainwright & Co. Maintains Invivyd (IVVD) Buy Recommendation - Nasdaq
H.C. Wainwright Maintains Invivyd(IVVD.US) With Buy Rating, Raises Target Price to $10 - 富途牛牛
Invivyd (IVVD) Analyst Rating: HC Wainwright Raises Price Target to $10 | IVVD Stock News - GuruFocus
Invivyd Highlights Antibody Development in New Presentation - MSN
Invivyd (IVVD) Price Target Increased by 88.89% to 5.78 - MSN
Why Invivyd Inc. stock is popular among millennialsTrade Volume Summary & Weekly High Momentum Picks - newser.com
Real time pattern detection on Invivyd Inc. stockWeekly Gains Summary & Growth Focused Stock Reports - newser.com
Candlestick signals on Invivyd Inc. stock todayOil Prices & High Yield Stock Recommendations - newser.com
Invivyd, Inc. (NASDAQ:IVVD) Given Average Rating of "Hold" by Brokerages - MarketBeat
[8-K] Invivyd, Inc. Reports Material Event | IVVD SEC FilingForm 8-K - Stock Titan
Invivyd, Inc. (IVVD) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID PreventionSlideshow (NASDAQ:IVVD) 2025-10-30 - Seeking Alpha
Invivyd, Inc. (IVVD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Using Python tools to backtest Invivyd Inc. strategiesJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - newser.com
Can Invivyd Inc. stock surprise with earnings upsideJuly 2025 Price Swings & AI Driven Price Forecasts - fcp.pa.gov.br
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - The Manila Times
Invivyd, Inc. to Host Webcast on REVOLUTION Clinical Program for VYD2311 Monoclonal Antibody Candidate Against COVID-19 - Quiver Quantitative
Invivyd (Nasdaq: IVVD) to host VYD2311 REVOLUTION webcast live at 8:30 a.m. ET - Stock Titan
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lee Timothy Edward | Chief Commercial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
88,987 |
| Duke William E. | Chief Financial Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Duke William E. | Chief Financial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Green Julie | Chief Human Resources Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Green Julie | Chief Human Resources Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 19 '25 |
Sale |
0.57 |
49,402 |
27,991 |
84,446 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 18 '25 |
Sale |
0.65 |
33,352 |
21,685 |
133,848 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 19 '25 |
Sale |
0.57 |
27,420 |
15,536 |
53,068 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 18 '25 |
Sale |
0.65 |
18,512 |
12,037 |
80,488 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):